Prevention of Paclitaxel-induced Neuropathic Pain in Patients With Planned Paclitaxel Chemotherapy (PrevTel)
Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
Phase IIa clinical trial will be conducted with patients requiring in-label
paclitaxel-chemotherapy due to ovarian or breast cancer. The efficacy of a 12-week
telmisartan treatment, starting one week before planned paclitaxel-administration to prevent
PIPNP (paclitaxel-induced peripheral neuropathic pain) will be assessed by measurement of
occurrence of clinical symptoms of PIPNP as well as lipid profiles